TickerGuard
Buy Day today: Neutral (60) Mixed market breadth · no major macro event
HYPR

Hyperfine Inc

Healthcare · Medical Devices

0.8938$ +2.5% vs. previous close Closing price · As of: Oct 2, 2026

Statements

Balance Sheet

Hyperfine Inc (HYPR) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 63 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet HYPR
Line item Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
– – – 72 208 86 81 202 179 162 148 134 122 113 103 94 85 77 69 59 53 45 42 55 60 63
26 – – 68 1.4 83 76 197 174 157 144 129 117 108 98 89 80 71 64 54 48 40 37 51 56 59
26 – – 63 0.9 77 65 188 162 145 132 118 104 94 85 75 63 54 46 38 33 25 22 35 41 43
26 – – 63 0.9 77 65 188 162 145 132 118 104 94 85 75 63 54 46 38 33 25 22 35 41 43
– – – 0.2 0.7 0.5 1.0 0.6 2.4 3.1 4.2 3.1 3.7 4.6 3.1 4.1 6.2 7.5 9.1 8.3 7.3 6.9 6.3 6.5 5.8 5.8
– – – 1.7 2.1 2.1 2.8 4.3 4.5 4.6 4.0 4.6 5.7 6.0 6.9 6.6 7.3 7.5 7.0 5.8 4.6 4.9 5.8 7.1 6.3 6.8
– – – 1.9 2.2 2.2 3.3 3.8 3.9 3.5 3.4 3.2 3.1 3.1 – – – – – – – – – – – –
-29 – – 4.3 7.4 5.1 182 16 12 11 13 10 9.4 9.3 9.3 9.8 9.8 9.8 11 9.9 10 10 15 14 26 26
– – – 4.1 0.1 4.9 14 16 11 10 12 8.8 8.0 8.0 8.2 8.8 8.8 8.8 10.0 8.7 8.0 8.0 10 12 10 9.6
– – – 1.4 – – 4.5 10 – – – – – 4.0 4.9 0.2 0.2 0.2 0.1 0.3 0.3 0.2 0.2 0.2 0.2 0.2
– – – 0.9 1.0 1.0 4.9 2.2 1.7 1.7 0.7 0.7 1.7 1.4 0.9 1.2 2.5 2.2 1.4 1.6 2.3 3.0 3.7 4.1 4.6 2.4
– – – 0.2 – – 0.2 – – – – – – – – – – – – – – – – – 13 13
29 – – 67 201 81 67 186 167 151 135 124 113 103 94 84 76 67 58 49 43 35 27 41 34 37
– – – -71 -0.2 -94 -110 -136 -160 -183 -196 -209 -222 -232 -243 -254 -264 -274 -284 -294 -304 -313 -324 -330 -339 -348
4.6 4.6 4.6 70 70 70 70 70 70 70 71 71 71 71 71 72 72 72 73 73 76 78 79 94 98 100

Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?